ALLMedicine™ Indolent Lymphoma Center
Research & Reviews 244 results
https://clinicaltrials.gov/ct2/show/NCT04933617
Jan 20th, 2023 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833869
BMC Immunology; Lutz C, Feiten S et. al.
Jan 12th, 2023 - Patients with indolent B-cell non-Hodgkin lymphomas (B-NHLs) have an increased risk of infections which is caused by pathomechanisms of the diseases itself but also as a result of anti-tumor therapy. Especially the effects of anti-CD20 antibodies ...
https://clinicaltrials.gov/ct2/show/NCT01938001
Jan 9th, 2023 - Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is a...
https://doi.org/10.1200/JCO.22.02403
Journal of Clinical Oncology : Official Journal of the Am... McLaughlin P, Grillo-López AJ et. al.
Jan 6th, 2023 - The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less imm...
https://doi.org/10.1002/ajh.26807
American Journal of Hematology; Chohan KL, Paludo J et. al.
Jan 3rd, 2023 - Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for the time of diagno...
Guidelines 1 results
https://doi.org/10.1007/s12094-010-0592-7
Clinical & Translational Oncology : Official Publication ... Rodríguez-Abreu D, Llanos Muñoz M et. al.
Oct 27th, 2010 - Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin's lymphoma (NHL) in the Western world. FL constitutes the most frequent indolent lymphoma, well characterized by its clinical presentation related to nodal involvement and i...
Drugs 1 results see all →
Clinicaltrials.gov 48 results
https://clinicaltrials.gov/ct2/show/NCT04933617
Jan 20th, 2023 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...
https://clinicaltrials.gov/ct2/show/NCT01938001
Jan 9th, 2023 - Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is a...
https://clinicaltrials.gov/ct2/show/NCT04431635
Dec 14th, 2022 - Patients with relapsed/refractory lymphoma generally have few if any curative options and demonstrate poor response rates to standard salvage therapies. Novel regimens utilizing molecular targets are needed to improve outcomes in this patient popu...
https://clinicaltrials.gov/ct2/show/NCT02953509
Dec 9th, 2022 - The primary objectives of this study are: To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, ge...
https://clinicaltrials.gov/ct2/show/NCT05326243
Oct 26th, 2022 - Cluster of differentiation (CD) 19 chimeric antigen receptor T-cell (CAR-T) has been a very promising treatment option for multiple types of B-cell lymphoma. Kymriah® (tisagenlecleucel, Novartis) and Yescarta® (axicabtagene ciloleucel, Gilead) wer...
News 157 results
https://www.onclive.com/view/loncastuximab-tesirine-rituximab-elicits-promising-anti-tumor-activity-in-relapsed-refractory-dlbcl
Oct 24th, 2022 - Loncastuximab tesirine-lpyl (Zynlonta) combined with rituximab (Rituxan) demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to data from p...
https://www.onclive.com/view/dr-orellana-noia-on-the-patient-population-of-the-polarix-trial-in-dlbcl
Sep 23rd, 2022 - Victor M. Orellana-Noia, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the patient population of the phase 3 POLARIX trial (NCT03274492) in diffuse large B-cell lymphoma (DLB...
https://www.onclive.com/view/fda-accepts-sbla-for-polatuzumab-vedotin-plus-r-chp-in-untreated-dlbcl
Aug 24th, 2022 - The FDA has accepted a supplemental biologics license application (sBLA) for the combination of polatuzumab vedotin-piiq (Polivy) and R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) as a treatment for patients with previ...
https://www.onclive.com/view/fda-approval-insights-liso-cel-in-second-line-relapsed-refractory-lbcl
Jul 28th, 2022 - Welcome to OncLive On Air®! I’m your host today, Caroline Seymour. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital ...
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl
Jun 29th, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...
